Drugs / VT3989
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04665206 | Mar 2021 → Nov 2029 expected | mesothelioma, non-small cell lung carcinoma | Vivace Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT3989 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04665206 ↗ |
| Action | Inhibit | “VT3989, a first-in-class potent oral TEAD palmitoylation inhibitor, disrupts YAP transcriptional activity.” PMID 41111090 ↗ Oct 2025 |